| 000 | 01821 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250516125123.0 | ||
| 264 | 0 | _c20130905 | |
| 008 | 201309s 0 0 eng d | ||
| 022 | _a1932-6203 | ||
| 024 | 7 |
_a10.1371/journal.pone.0052095 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWang, Guan | |
| 245 | 0 | 0 |
_aClass I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. _h[electronic resource] |
| 260 |
_bPloS one _c2012 |
||
| 300 |
_ae52095 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aCell Cycle Checkpoints _xdrug effects |
| 650 | 0 | 4 |
_aCell Death _xdrug effects |
| 650 | 0 | 4 |
_aCell Division _xdrug effects |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCyclin-Dependent Kinase Inhibitor p21 _xmetabolism |
| 650 | 0 | 4 | _aDNA Breaks, Double-Stranded |
| 650 | 0 | 4 |
_aEpithelial Cells _xdrug effects |
| 650 | 0 | 4 |
_aG2 Phase _xdrug effects |
| 650 | 0 | 4 |
_aHistone Deacetylase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aHistone Deacetylases _xmetabolism |
| 650 | 0 | 4 |
_aHistones _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 650 | 0 | 4 |
_aPancreatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aTubulin _xmetabolism |
| 700 | 1 | _aHe, Jing | |
| 700 | 1 | _aZhao, Jianyun | |
| 700 | 1 | _aYun, Wenting | |
| 700 | 1 | _aXie, Chengzhi | |
| 700 | 1 | _aTaub, Jeffrey W | |
| 700 | 1 | _aAzmi, Asfar | |
| 700 | 1 | _aMohammad, Ramzi M | |
| 700 | 1 | _aDong, Yan | |
| 700 | 1 | _aKong, Wei | |
| 700 | 1 | _aGuo, Yingjie | |
| 700 | 1 | _aGe, Yubin | |
| 773 | 0 |
_tPloS one _gvol. 7 _gno. 12 _gp. e52095 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1371/journal.pone.0052095 _zAvailable from publisher's website |
| 999 |
_c22357112 _d22357112 |
||